Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus.

@article{Hu2016ExenatideTD,
  title={Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus.},
  author={Yan Hu and Jia Liu and H Zhang and Yi'' Wendy'' Xu and Tianpei Hong and Guang Wang},
  journal={Diabetes & metabolism},
  year={2016},
  volume={42 5},
  pages={358-363}
}
AIM Fibroblast growth factor 21 (FGF21) has been demonstrated to be a metabolic regulator with beneficial effects. Several studies have shown that type 2 diabetes mellitus (T2DM) patients have increased FGF21 levels and decreased expression of FGF receptors, suggesting a state of 'FGF21 resistance'. The aim of this study was to investigate the effects of the glucagon-like peptide (GLP)-1 receptor agonist exenatide on FGF21 levels and other metabolic parameters in patients with newly diagnosed… CONTINUE READING